CP...was the Motley Fool article posted after market close today? I did not see a time stamp on it showing what time it was released. I'm curious because if it was made public during today's trading, it didn't have any positive effect on the PPS. I'm curious.
Biotech investing is pure unadulterated blind faith driven investing. The aura of uncertainty is present right up to the last second of an acquisition. The clues can be misleading...the path can be twisty...the potential rewards surreal!
I don't know if this got enough notice on Friday so I thought I'd post the part about PPHM.
This article was posted by CP and was published on Friday by Motley Fool....
3 Biotech Companies That Could Be the Next Intercept or InterMune With Intercept and InterMune stocks jumping 525% and 171%, respectively, biotech-savvy investors are eagerly looking for the next big thing. It just might be one of these three companies.
Simply put, biotech stocks are on fire. Venture capital is pouring into the sector, with 38 companies completing IPOs in 2013 and a number of others slated to go public this year. It's not hard to see why when performance data on Finviz shows that 196 of 228 biotech stocks are up year to date. And some aren't just up -- they've absolutely soared...
Peregrine Pharmaceuticals (NASDAQ: PPHM) Peregrine Pharmaceuticals went on a wild ride in 2012, with shares rising from roughly $0.40 to above $5 following midstage data on bavituximab, its second-line drug for nonsmall cell lung cancer, or NSCLC. The ride wouldn't last long, though, with the stock crashing down by more than 80% after Peregrine noted, just weeks later, that the data shouldn't be trusted because of errors at a third-party clinical contractor. By the time all was said and done, months later, Peregrine Pharmaceuticals had reported a statistically impressive 116% improvement in median overall survival to 12.1 months, but its data was largely dismissed by investors who didn't know what to believe.
Peregrine's phase 3 study of bavituximab known as SUNRISE will soon help decide which side is correct. The trial compares the combination of bavituximab and docetaxel against a control arm, with the primary endpoint being a statistically significant improvement in overall survival.
What's particularly unique, and the reason investors should pay close attention to Peregrine, is that bavituximab is one entrant into the extremely competitive race to develop cancer immunotherapies, which train the body's immune system to recognize and attack previously undetected cancer cells. Bavituximab works by blocking phosphatidylserine, which is an immunosuppressive molecule found on the outside of cancer cells that allows them to remain undetected by the body's immune system. If successful, bavituximab could revolutionize the second-line treatment for NSCLC, and it may hold promise as a first-line treatment, too.
Keep in mind, though, that small-cap biopharmas have a very poor track record of success when it comes to phase 3 oncology-based trials.
News 
Market Data 
Discover 
